LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Open

SectorHealthcare

19.68 -2.09

Buy Sell

Overview

Share price change

24h

Current

Min

19.31

Max

20.12

Key metrics
By Trading Economics
Income	4.8M -36M
Sales	6.1M 116M
Profit margin	-30.977
Employees	1,869
EBITDA	24M -31M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+104.59% upside

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-766M 2.2B
Previous open	21.77
Previous close	19.68

News Sentiment

By Acuity

40%

60%

108 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 lut 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 lut 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 lut 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 lut 2026, 23:21 UTC

Earnings

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 lut 2026, 23:20 UTC

Earnings

Nickel Industries 2025 Operating Profit US$126.4 Million

22 lut 2026, 23:19 UTC

Earnings

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 lut 2026, 23:19 UTC

Earnings

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 lut 2026, 23:18 UTC

Earnings

Nickel Industries Won't Pay a Final Dividend

22 lut 2026, 23:16 UTC

Earnings

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 lut 2026, 21:35 UTC

Earnings

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 lut 2026, 21:34 UTC

Earnings

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 lut 2026, 21:34 UTC

Earnings

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 lut 2026, 21:33 UTC

Earnings

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 lut 2026, 21:33 UTC

Earnings

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 lut 2026, 21:28 UTC

Earnings

Ampol Final Dividend A$0.60/Share

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Revenue A$31.37 Billion, Down 10%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 lut 2026, 14:31 UTC

Acquisitions, Mergers, Takeovers

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 lut 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 lut 2026, 23:12 UTC

Acquisitions, Mergers, Takeovers

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 lut 2026, 22:12 UTC

Earnings

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 lut 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 lut 2026, 21:23 UTC

Earnings

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 lut 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 lut 2026, 21:01 UTC

Acquisitions, Mergers, Takeovers

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 lut 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

104.59% upside

12 Months Forecast

Average 41 USD 104.59%

High 53 USD

Low 35 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

108 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.